AFE1F307-45A7-4155-8D51-FEBD6C92947C
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 9.395532194480946
- age_years
- 74
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.626
- INTERFERON_ALPHA_RESPONSE+0.570
- G2M_CHECKPOINT+0.558
- MYC_TARGETS_V1+0.555
- DNA_REPAIR+0.517
- MYC_TARGETS_V2+0.503
- INTERFERON_GAMMA_RESPONSE+0.481
- MTORC1_SIGNALING+0.470
- ANGIOGENESIS+0.451
- UNFOLDED_PROTEIN_RESPONSE+0.451
Top 10 suppressed
- KRAS_SIGNALING_DN-0.394
- PANCREAS_BETA_CELLS-0.316
- HEDGEHOG_SIGNALING-0.245
- APICAL_SURFACE-0.208
- SPERMATOGENESIS-0.156
- ESTROGEN_RESPONSE_EARLY-0.131
- MYOGENESIS-0.057
- KRAS_SIGNALING_UP-0.015
- UV_RESPONSE_DN-0.003
- ANDROGEN_RESPONSE+0.033
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | EC1C727A-1F71-4C09-B867-7F163424D463 | — | — | 0.964 |
| 2 | 33800B09-6DCC-4BE8-891C-5F34ADAC65B3 | — | — | 0.964 |
| 3 | C3F0BD22-6891-44F0-B023-02FC6EDFA7EB | — | — | 0.961 |
| 4 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.958 |
| 5 | CC9815B3-88D0-4376-B96F-B979E1FBD0C7 | — | — | 0.956 |
| 6 | A462D32E-3A6A-4E00-A4A7-BAF374D6009C | — | — | 0.956 |
| 7 | 9BB12A25-E833-4055-8CEF-814EA5454F11 | — | — | 0.955 |
| 8 | DE370889-1057-4355-AFD8-CCFCDC6CD00F | — | — | 0.954 |
| 9 | 30D8578D-0B48-4D03-9E39-6425494ECD5C | — | — | 0.952 |
| 10 | 821FCEC2-41D4-48D9-8B75-D87405D075F7 | — | — | 0.950 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.626 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.558 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.555 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.517 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.503 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.481 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.451 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.451 | Idelalisib | — uncovered |
| HYPOXIA | 0.439 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.427 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.414 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.389 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.387 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.376 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.374 | Inavolisib | — uncovered |
| APOPTOSIS | 0.350 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.341 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.337 | Idelalisib | — uncovered |